Observational study of FOLFOX therapy for esophageal squamous cell carcinoma

Observational study of definitive chemoradiotherapy and palliative chemotherapy using FOLFOX for esophageal squamous cell carcinoma - OFFER

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044485

Enrollment

Registered

2021-06-09

Start date

2021-03-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal squamous cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Cervical or thoracic esophageal cancer, or esophagogastric junction cancer (UICC 8th) 2. Histologically proven squamous cell carcinoma 3. Intolerable to cisplatin and planned either of the treatment: definitive chemoradiotherapy for stage I-IVA disease; palliative first-line chemotherapy for stage IVB or recurrent disease; salvage chemotherapy after refractory to another platinum for stage IVB or recurrent disease 4. No previous use of oxaliplatin 5. 20 years or older 6. ECOG performance status 0, 1, 2 7. Adequate organ functions 8. Obtained informed consent

Exclusion criteria

Exclusion criteria: Patient who does not satisfy inclusion criteria

Design outcomes

Primary

Measure	Time frame
Group A: Complete response rate Group B and C: response rate	—

Secondary

Measure	Time frame
Overall survival, progression free survival, adverse events	—

Countries

Japan

Contacts

Public ContactKunihiro Fushiki

Shizuoka Cancer Center Division of Gastrointestinal Oncology

k.fushiki@scchr.jp0559895222

Outcome results